Navigation Links
AbGenomics International has raised $9.6 million for advancing its psoriasis phase-II trials in US
Date:7/17/2013

LOS ALTOS, Calif., July 17, 2013 /PRNewswire-iReach/ -- AbGenomics International announced today that it has raised $9.6 million in current financing round. 

(Photo: http://photos.prnewswire.com/prnh/20130717/MN49038)

AbGenomics will use the proceeds to continue advancing its therapeutic antibodies for autoimmune diseases and cancers. AbGenomics' lead drug candidate AbGn-168H, a first-in-class humanized monoclonal antibody that specifically depletes chronic activated T cells for the treatment of autoimmune diseases, is in Phase II clinical trials for psoriasis. The evaluation of additional AbGn-168H trials for Crohn's/IBD, type-I diabetes, MS, and RA indications are ongoing. The company plans to advance another therapeutic candidate, AbGn-107, an antibody drug conjugate with fully owned first-in-class linker-payload, into phase-I clinical trial for the treatment of pancreatic and stomach tumors early next  year.  "We are delighted to have the continuing support of our investors. This round of financing provides AbGenomics additional capital to continue its clinical-stage programs through proof of concept for addressing major unmet needs in autoimmune diseases and advance its first-in-class antibody drug conjugate technology for cancers." said Dr. Rong-Hwa Lin, Founder and CEO of AbGenomics.

About AbGenomics (www.abgenomics.com) AbGenomics is a biopharmaceutical company focused on the discovery and development of novel medicines to treat diseases with unmet medical need and significant market potential. The Company's strategy is to commercialize its novel products in collaboration with major pharmaceutical partners in order to maximize the opportunity for development and marketing of the Company's compounds.

Media Contact: RUTH LI, ABGENOMICS INTERNATIONAL INC., 6509889912, RUTH.LI@ABGENOMICS.COM

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE AbGenomics International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AbGenomics International Obtains FDA Agreement on Its Phase 2 Clinical Trial Plans
2. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
3. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
4. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
5. SurgLine International, Inc. Launches A Wholly Owned Operating Subsidiary To Pursue Cost Containment Strategies
6. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
7. Chindex International, Inc. to Report First Quarter 2012 Financial Results
8. VWR International, LLC Signs Agreement to Acquire basan Germany GmbH
9. Pharmaceutics International, Inc. (Pii) Supports University Pharmaceutical Technology Education and Research
10. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
11. Bacterin International Signs Its Third National GPO Contract with Novation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; ... program in the use of cannabinoids for the ... June, 2015 InMed initiated its COPD program using ... and potential active compounds that can be useful ... vitro assays using human lung fibroblasts (HFL-1 cell ...
(Date:12/5/2016)... , Dec. 5, 2016  Balloon catheter is an ... is inserted into the femoral artery in the leg ... to treat constricted blood vessels. These products are generally ... atherosclerosis – deposition of lipid substances in the blood ... market is projected to expand at a CAGR of ...
(Date:12/5/2016)... 5, 2016 Spain Glaucoma Surgery Devices Market ... "Spain Glaucoma Surgery Devices Market Outlook to 2022", provides ... market. The report provides value, in millions of US ... market segements - Canaloplasty Micro Catheters and Glaucoma Drainage ... distribution shares data for each of these market segements, ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... The medical profession is ... winter seasons. One major study analyzing heart attacks among 138,602 people recorded a ... a given year. We would all agree of course–no time of year is a ...
(Date:12/7/2016)... ... December 07, 2016 , ... “The Road To Restoration”: ... trial, not a one hour a week showing of hands. “The Road To Restoration” ... begins, “Perhaps you are familiar with the brass ring that you could reach out ...
(Date:12/7/2016)... Caloifornia (PRWEB) , ... December 07, 2016 , ... ... present the fifth annual Business Architecture Innovation Summit in Reston, VA on March ... world who will share a range of experiences from a cross-section of industries ...
(Date:12/6/2016)... Korea (PRWEB) , ... December 06, 2016 , ... ... Inc. have agreed to collaborate in developing a vaccine against the Middle East ... a vaccine can be available in South Korea for emergency deployment in the ...
(Date:12/6/2016)... ... December 06, 2016 , ... i2i Population Health, a ... a vice president of sales. , “Ajdin understands that building a successful sales ... understand what each client needs, and is persistent in building towards a solution ...
Breaking Medicine News(10 mins):